News headlines Vertex Pharmaceuticals (VRTX) is gaining attention with promising developments in kidney treatments and solid earnings growth, although concerns linger about its reliance on cystic ...

With agentic AI, the database must evolve from a passive ledger to an active reasoning engine that informs, guides, and ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

Abstract: Graph neural networks (GNNs) have shown promise in graph classification tasks, but they struggle to identify out-of-distribution (OOD) graphs often encountered in real-world scenarios, ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their momentum that ...